An immunostimulatory glycolipid that blocks SARS-CoV-2, RSV, and influenza infections in vivo

Moriya Tsuji (), Manoj S. Nair, Kazuya Masuda, Candace Castagna, Zhenlu Chong, Tamarand L. Darling, Kuljeet Seehra, Youngmin Hwang, Ágata Lopes Ribeiro, Geovane Marques Ferreira, Laura Corredor, Jordana Grazziela Alves Coelho-dos-Reis, Yukiko Tsuji, Munemasa Mori, Adrianus C. M. Boon, Michael S. Diamond, Yaoxing Huang () and David D. Ho ()
Additional contact information
Moriya Tsuji: Columbia University Irving Medical Center
Manoj S. Nair: Columbia University Irving Medical Center
Kazuya Masuda: Columbia University Irving Medical Center
Candace Castagna: Columbia University Irving Medical Center
Zhenlu Chong: Washington University School of Medicine
Tamarand L. Darling: Washington University School of Medicine
Kuljeet Seehra: Washington University School of Medicine
Youngmin Hwang: Columbia University Irving Medical Center
Ágata Lopes Ribeiro: Federal University of Minas Gerais
Geovane Marques Ferreira: Federal University of Minas Gerais
Laura Corredor: Columbia University Irving Medical Center
Jordana Grazziela Alves Coelho-dos-Reis: Federal University of Minas Gerais
Yukiko Tsuji: Columbia University Irving Medical Center
Munemasa Mori: Columbia University Irving Medical Center
Adrianus C. M. Boon: Washington University School of Medicine
Michael S. Diamond: Washington University School of Medicine
Yaoxing Huang: Columbia University Irving Medical Center
David D. Ho: Columbia University Irving Medical Center

Nature Communications, 2023, vol. 14, issue 1, 1-12

Abstract: Abstract Prophylactic vaccines for SARS-CoV-2 have lowered the incidence of severe COVID-19, but emergence of viral variants that are antigenically distinct from the vaccine strains are of concern and additional, broadly acting preventive approaches are desirable. Here, we report on a glycolipid termed 7DW8-5 that exploits the host innate immune system to enable rapid control of viral infections in vivo. This glycolipid binds to CD1d on antigen-presenting cells and thereby stimulates NKT cells to release a cascade of cytokines and chemokines. The intranasal administration of 7DW8-5 prior to virus exposure significantly blocked infection by three different authentic variants of SARS-CoV-2, as well as by respiratory syncytial virus and influenza virus, in mice or hamsters. We also found that this protective antiviral effect is both host-directed and mechanism-specific, requiring both the CD1d molecule and interferon- $$\gamma$$ γ . A chemical compound like 7DW8-5 that is easy to administer and cheap to manufacture may be useful not only in slowing the spread of COVID-19 but also in responding to future pandemics long before vaccines or drugs are developed.

Date: 2023
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-023-39738-1 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:14:y:2023:i:1:d:10.1038_s41467-023-39738-1

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-023-39738-1

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().